Integra LifeSciences Launches Pediatric Registry for AERA System

Integra LifeSciences Initiates Pediatric AERA Registry

Integra LifeSciences Holding Corporation (Nasdaq: IART), a premier global leader in medical technology, has taken a significant step forward by enrolling the first patient in the Acclarent AERA Pediatric Registry. This multi-center observational registry aims to evaluate the real-world applications of the AERA Eustachian Tube Balloon Dilation System in pediatric patients.

The Purpose Behind the AERA Pediatric Registry

The launch of this registry reflects a dedicated effort to assess the clinical performance of AERA in children suffering from obstructive Eustachian tube dysfunction (ETD). Dr. Prasad Thottam, affiliated with Michigan Pediatric ENT Associates, celebrated this inaugural enrollment, emphasizing the pride in being the first to register a patient for this important initiative.

Comprehensive Data Collection and Analysis

The Acclarent AERA Pediatric Registry is strategically designed to monitor both safety and efficacy outcomes from around 300 pediatric patients who will undergo Eustachian tube balloon dilation (ETBD) using the AERA system. Dr. Thottam noted, “Our ongoing commitment to understanding and treating pediatric Eustachian tube dysfunction underscores the importance of this registry.” He added that this advancement signifies a collaborative goal to enhance pediatric ear, nose, and throat (ENT) care and underscores Integra's dedication to supporting safe and evidence-based medical innovations.

Registry Goals and Objectives

One of the registry's primary objectives is to achieve a failure-free status following ETBD with the AERA device. Failure is classified as the necessity for revision surgery, which could include further ETBD sessions, tympanostomy tube placements, or adenoidectomies due to ongoing ETD issues. Additionally, secondary benchmarks encompass various assessments, such as tympanogram results, pure tone audiometry, and patient-reported experiences.

Evaluating Safety and Effectiveness

The registry is set to gather critical insights on successful balloon dilation rates throughout procedures, while closely monitoring any adverse events or complications that arise as part of the safety evaluation framework. Integra anticipates participation from up to 20 locations across the U.S., promising a diverse and rich data repository that will not only enhance understanding but also foster improved reimbursement policies and clinical acceptance.

About Integra LifeSciences

Integra LifeSciences has its mission rooted in the restoration of patient lives through innovative treatment pathways. They focus on enhancing patient outcomes while also setting new benchmarks in surgical, neurologic, and regenerative care. Their extensive portfolio champions high-quality, leading medical technology, all aimed at advancing healthcare.

Further Information on Integra LifeSciences

For those interested in keeping up with the latest developments regarding Integra and their comprehensive array of products, details can be found on their official website. This serves as a valuable resource for healthcare professionals and patients alike, aiming for better health outcomes through cutting-edge medical solutions.

Frequently Asked Questions

What is the Acclarent AERA Pediatric Registry?

The registry is a multi-center observational study aimed at evaluating the use of the AERA Eustachian Tube Balloon Dilation System in treating pediatric patients with Eustachian tube dysfunction.

Who is involved in the registry?

The registry involves pediatric ENT specialists and will enroll up to 300 young patients across various sites in the U.S.

What type of data will the registry collect?

The registry will collect safety and efficacy outcomes from procedures, including success rates, audiology assessments, and patient-reported feedback.

Why is the registry important?

This registry aims to improve understanding of ETD treatments and optimize pathways for reimbursement and clinical adoption of innovative treatments in pediatric care.

How can I learn more about Integra LifeSciences?

For more information and the latest updates, visit Integra LifeSciences’ official website, which provides insights into their products and advancements in medical technology.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.